- Home
- SCS vs ELVN Comparison
SCS vs ELVN Comparison
Compare SCS & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCS
- ELVN
- Stock Information
- Founded
- SCS 1912
- ELVN 2016
- Country
- SCS United States
- ELVN United States
- Employees
- SCS N/A
- ELVN N/A
- Industry
- SCS Office Equipment/Supplies/Services
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- SCS Consumer Discretionary
- ELVN Health Care
- Exchange
- SCS Nasdaq
- ELVN Nasdaq
- Market Cap
- SCS 1.2B
- ELVN 1.2B
- IPO Year
- SCS 1998
- ELVN 2020
- Fundamental
- Price
- SCS $11.25
- ELVN $20.73
- Analyst Decision
- SCS Buy
- ELVN Strong Buy
- Analyst Count
- SCS 1
- ELVN 5
- Target Price
- SCS $16.00
- ELVN $41.20
- AVG Volume (30 Days)
- SCS 1.1M
- ELVN 747.2K
- Earning Date
- SCS 06-25-2025
- ELVN 08-12-2025
- Dividend Yield
- SCS 3.56%
- ELVN N/A
- EPS Growth
- SCS 37.12
- ELVN N/A
- EPS
- SCS 1.04
- ELVN N/A
- Revenue
- SCS $3,217,700,000.00
- ELVN N/A
- Revenue This Year
- SCS $4.20
- ELVN N/A
- Revenue Next Year
- SCS $4.09
- ELVN N/A
- P/E Ratio
- SCS $10.81
- ELVN N/A
- Revenue Growth
- SCS 2.64
- ELVN N/A
- 52 Week Low
- SCS $9.32
- ELVN $13.30
- 52 Week High
- SCS $14.74
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- SCS 62.85
- ELVN 52.08
- Support Level
- SCS $9.70
- ELVN $19.22
- Resistance Level
- SCS $11.40
- ELVN $21.90
- Average True Range (ATR)
- SCS 0.42
- ELVN 1.49
- MACD
- SCS 0.08
- ELVN -0.19
- Stochastic Oscillator
- SCS 91.18
- ELVN 39.43
About SCS Steelcase Inc.
Steelcase Inc is a furniture company based in the United States. Its brands, such as Steelcase, AMQ, Coalesse, Designtex, and others, offer a portfolio of furniture and architectural products and services designed to help customers create workplaces. It markets its products and services to businesses and organizations predominantly through a network of dealers and also sells to consumers in markets around the world through web-based and retail distribution channels. The company's reportable segments include the Americas, which generates key revenue, and the International segment.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.